CurrentEndo
Get Weekly

CurrentEndo coverage · page 7 of 55

Diabetes, Obesity and Metabolism

Briefs 241–280 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

    Cross-sectional studyComplications

  2. Diabetes Obes Metab

    Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study

    Randomized controlled trialObesity

  3. Diabetes Obes Metab

    A Cross‐Nationally Validated Nomogram for Cardiometabolic Multimorbidity in Overweight/Obese Older Adults: CHARLS and HRS Cohorts

    Diagnostic or prognostic studyObesity

  4. Diabetes Obes Metab

    Cardiovascular Outcomes With Tirzepatide Versus GLP ‐1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta‐Analysis

    Meta-analysisObesity

  5. Diabetes Obes Metab

    Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials

    Meta-analysisT1D

  6. Diabetes Obes Metab

    Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis

    Meta-analysisT2D & other

  7. Diabetes Obes Metab

    GLP ‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study

    Cohort studyObesity

  8. Diabetes Obes Metab

    Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

    Cohort studyObesity

  9. Diabetes Obes Metab

    Trends in Prevalence of Diabetes, Pre‐Diabetes, and Cardiometabolic Risk Factor Control Among U.S. Adults, 2013–2023

    Cross-sectional studyT2D & other

  10. Diabetes Obes Metab

    First‐Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial

    Randomized controlled trialT2D & other

  11. Diabetes Obes Metab

    A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline

    Research articleT2D & other

  12. Diabetes Obes Metab

    Efficacy and Safety of Intensifying Once‐Weekly Insulin Icodec Treatment With Once‐Weekly Semaglutide in Adults With Type 2 Diabetes: A Single‐Arm, Open‐Label, Treat‐to‐Target, Phase 3b Trial ( ONWARDS 8)

    Research articleT2D & other

  13. Diabetes Obes Metab

    Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec

    Research articleT2D & other

  14. Diabetes Obes Metab

    Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan ‐O‐ AP and LixiLan ‐L‐ CN

    Secondary analysisT2D & other

  15. Diabetes Obes Metab

    Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

    Meta-analysisObesity

  16. Diabetes Obes Metab

    Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE ‐O Trial

    Secondary analysisT2D & other

  17. Diabetes Obes Metab

    Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study

    Cohort studyT1D

  18. Diabetes Obes Metab

    GLP ‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

    Research articleT1D

  19. Diabetes Obes Metab

    Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study

    Cohort studyT2D & other

  20. Diabetes Obes Metab

    Modelling the Clinical and Complication‐Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China

    Research articleT2D & other

  21. Diabetes Obes Metab

    Pubertal Stage–Based One‐hour Postload Glucose Thresholds Improve Identification of Prediabetes and Type 2 Diabetes in Children With Overweight or Obesity

    Cross-sectional studyObesity

  22. Diabetes Obes Metab

    Impact of Autoimmune Hypothyroidism and Celiac Disease on Progression to Diabetes in Individuals Positive for GAD65 or IA ‐2 Autoantibodies

    Cohort studyT1D

  23. Diabetes Obes Metab

    Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study

    Cohort studyT2D & other

  24. Diabetes Obes Metab

    Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease

    Cohort studyComplications

  25. Diabetes Obes Metab

    Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan

    Cohort studyT2D & other

  26. Diabetes Obes Metab

    Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT ‐1 and SURMOUNT ‐2 Trials

    Secondary analysisObesity

  27. Diabetes Obes Metab

    Glycaemic Control During School Days and Holidays in Children and Adolescents With Type 1 Diabetes Using Open‐Source Android Artificial Pancreas Systems: A Real‐World Study

    Cohort studyTechnology

  28. Diabetes Obes Metab

    Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

    Cohort studyLipids & liver

  29. Diabetes Obes Metab

    Prevalence of Obesity and Related Conditions and GLP ‐1 Use in Medicare Fee‐for‐Service Beneficiaries

    Cohort studyT2D & other

  30. Diabetes Obes Metab

    The Impact of Hypoglycaemia on Quality of Life in Adults With Type 1 Diabetes Using Contemporary Diabetes Technologies: A US National Survey

    Cross-sectional studyComplications

  31. Diabetes Obes Metab

    Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial

    Meta-analysis

  32. Diabetes Obes Metab

    Genetic and Environmental Effects on BMI Fluctuation Across the Adult Life Course and Its Associations With Baseline BMI and BMI Change: An Individual‐Based Study of 14 Longitudinal Twin Cohorts

    Meta-analysisObesity

  33. Diabetes Obes Metab

    Efficacy and Safety of GLP ‐1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis

    Meta-analysisT2D & other

  34. Diabetes Obes Metab

    A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

    Secondary analysisT2D & other

  35. Diabetes Obes Metab

    Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

    Meta-analysisObesity

  36. Diabetes Obes Metab

    The Burden of Alzheimer’s Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023

    Secondary analysis

  37. Diabetes Obes Metab

    Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

    Secondary analysisT2D & other

  38. Diabetes Obes Metab

    Effects of Weight‐Loss Interventions on Kidney, Cardiometabolic and Anthropometric Outcomes in Adults With CKD and Overweight or Obesity: A Systematic Review and Meta‐Analysis

    Meta-analysisObesity

  39. Diabetes Obes Metab

    Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

    Cohort study

  40. Diabetes Obes Metab

    Large‐Scale Proteomics Uncovers Pre‐Disease Inflammation–Lipid Subtypes to Refine Risk Stratification and Prediction of Type 2 Diabetes

    Cohort studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 241–280 of 2,200, newest first